Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Eradicating uropathogenic Escherichia coli biofilms with a ciprofloxacin-dinitroxide conjugate.

Verderosa AD, Harris J, Dhouib R, Totsika M, Fairfull-Smith KE.

Medchemcomm. 2019 Feb 25;10(5):699-711. doi: 10.1039/c9md00062c. eCollection 2019 May 1.

PMID:
31191860
2.

Profluorescent Fluoroquinolone-Nitroxides for Investigating Antibiotic⁻Bacterial Interactions.

Verderosa AD, Dhouib R, Fairfull-Smith KE, Totsika M.

Antibiotics (Basel). 2019 Mar 4;8(1). pii: E19. doi: 10.3390/antibiotics8010019.

3.

Author Correction: A shape-shifting redox foldase contributes to Proteus mirabilis copper resistance.

Furlong EJ, Lo AW, Kurth F, Premkumar L, Totsika M, Achard MES, Halili MA, Heras B, Whitten AE, Choudhury HG, Schembri MA, Martin JL.

Nat Commun. 2019 Mar 1;10(1):976. doi: 10.1038/s41467-019-08920-9.

4.

Moraxella catarrhalis NucM is an entry nuclease involved in extracellular DNA and RNA degradation, cell competence and biofilm scaffolding.

Tan A, Li WS, Verderosa AD, Blakeway LV, D Mubaiwa T, Totsika M, Seib KL.

Sci Rep. 2019 Feb 22;9(1):2579. doi: 10.1038/s41598-019-39374-0.

5.

Self-derived structure-disrupting peptides targeting methionine aminopeptidase in pathogenic bacteria: a new strategy to generate antimicrobial peptides.

Zhan J, Jia H, Semchenko EA, Bian Y, Zhou AM, Li Z, Yang Y, Wang J, Sarkar S, Totsika M, Blanchard H, Jen FE, Ye Q, Haselhorst T, Jennings MP, Seib KL, Zhou Y.

FASEB J. 2019 Feb;33(2):2095-2104. doi: 10.1096/fj.201700613RR. Epub 2018 Sep 27.

PMID:
30260702
6.

The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers.

Lim Y, Fukuma N, Totsika M, Kenny L, Morrison M, Punyadeera C.

Front Cell Infect Microbiol. 2018 Aug 3;8:267. doi: 10.3389/fcimb.2018.00267. eCollection 2018.

7.

Intestinal Colonization Traits of Pandemic Multidrug-Resistant Escherichia coli ST131.

Sarkar S, Hutton ML, Vagenas D, Ruter R, Schüller S, Lyras D, Schembri MA, Totsika M.

J Infect Dis. 2018 Aug 14;218(6):979-990. doi: 10.1093/infdis/jiy031.

8.

Inhibition of Diverse DsbA Enzymes in Multi-DsbA Encoding Pathogens.

Totsika M, Vagenas D, Paxman JJ, Wang G, Dhouib R, Sharma P, Martin JL, Scanlon MJ, Heras B.

Antioxid Redox Signal. 2018 Sep 1;29(7):653-666. doi: 10.1089/ars.2017.7104. Epub 2018 Feb 1.

9.

Oral Microbiome: A New Biomarker Reservoir for Oral and Oropharyngeal Cancers.

Lim Y, Totsika M, Morrison M, Punyadeera C.

Theranostics. 2017 Sep 26;7(17):4313-4321. doi: 10.7150/thno.21804. eCollection 2017. Review.

10.

YeeJ is an inverse autotransporter from Escherichia coli that binds to peptidoglycan and promotes biofilm formation.

Martinez-Gil M, Goh KGK, Rackaityte E, Sakamoto C, Audrain B, Moriel DG, Totsika M, Ghigo JM, Schembri MA, Beloin C.

Sci Rep. 2017 Sep 12;7(1):11326. doi: 10.1038/s41598-017-10902-0.

11.

The saliva microbiome profiles are minimally affected by collection method or DNA extraction protocols.

Lim Y, Totsika M, Morrison M, Punyadeera C.

Sci Rep. 2017 Aug 17;7(1):8523. doi: 10.1038/s41598-017-07885-3.

12.

A shape-shifting redox foldase contributes to Proteus mirabilis copper resistance.

Furlong EJ, Lo AW, Kurth F, Premkumar L, Totsika M, Achard MES, Halili MA, Heras B, Whitten AE, Choudhury HG, Schembri MA, Martin JL.

Nat Commun. 2017 Jul 19;8:16065. doi: 10.1038/ncomms16065. Erratum in: Nat Commun. 2019 Mar 1;10(1):976.

13.

Disarming pathogens: benefits and challenges of antimicrobials that target bacterial virulence instead of growth and viability.

Totsika M.

Future Med Chem. 2017 Mar;9(3):267-269. doi: 10.4155/fmc-2016-0227. Epub 2017 Feb 16. No abstract available.

14.

The cytochrome bd-I respiratory oxidase augments survival of multidrug-resistant Escherichia coli during infection.

Shepherd M, Achard ME, Idris A, Totsika M, Phan MD, Peters KM, Sarkar S, Ribeiro CA, Holyoake LV, Ladakis D, Ulett GC, Sweet MJ, Poole RK, McEwan AG, Schembri MA.

Sci Rep. 2016 Oct 21;6:35285. doi: 10.1038/srep35285.

15.

Differential Regulation of the Surface-Exposed and Secreted SslE Lipoprotein in Extraintestinal Pathogenic Escherichia coli.

Tan L, Moriel DG, Totsika M, Beatson SA, Schembri MA.

PLoS One. 2016 Sep 6;11(9):e0162391. doi: 10.1371/journal.pone.0162391. eCollection 2016.

16.

Comprehensive analysis of type 1 fimbriae regulation in fimB-null strains from the multidrug resistant Escherichia coli ST131 clone.

Sarkar S, Roberts LW, Phan MD, Tan L, Lo AW, Peters KM, Paterson DL, Upton M, Ulett GC, Beatson SA, Totsika M, Schembri MA.

Mol Microbiol. 2016 Sep;101(6):1069-87. doi: 10.1111/mmi.13442. Epub 2016 Jul 15.

17.

Biofilm formation by multidrug resistant Escherichia coli ST131 is dependent on type 1 fimbriae and assay conditions.

Sarkar S, Vagenas D, Schembri MA, Totsika M.

Pathog Dis. 2016 Apr;74(3). pii: ftw013. doi: 10.1093/femspd/ftw013. Epub 2016 Mar 2.

PMID:
26940589
18.

Molecular Characterization of the Vacuolating Autotransporter Toxin in Uropathogenic Escherichia coli.

Nichols KB, Totsika M, Moriel DG, Lo AW, Yang J, Wurpel DJ, Rossiter AE, Strugnell RA, Henderson IR, Ulett GC, Beatson SA, Schembri MA.

J Bacteriol. 2016 Apr 28;198(10):1487-98. doi: 10.1128/JB.00791-15. Print 2016 May 15.

19.

The role of H4 flagella in Escherichia coli ST131 virulence.

Kakkanat A, Totsika M, Schaale K, Duell BL, Lo AW, Phan MD, Moriel DG, Beatson SA, Sweet MJ, Ulett GC, Schembri MA.

Sci Rep. 2015 Nov 9;5:16149. doi: 10.1038/srep16149.

20.

Comparative proteomics of uropathogenic Escherichia coli during growth in human urine identify UCA-like (UCL) fimbriae as an adherence factor involved in biofilm formation and binding to uroepithelial cells.

Wurpel DJ, Totsika M, Allsopp LP, Webb RI, Moriel DG, Schembri MA.

J Proteomics. 2016 Jan 10;131:177-189. doi: 10.1016/j.jprot.2015.11.001. Epub 2015 Nov 3.

21.

Strain- and host species-specific inflammasome activation, IL-1β release, and cell death in macrophages infected with uropathogenic Escherichia coli.

Schaale K, Peters KM, Murthy AM, Fritzsche AK, Phan MD, Totsika M, Robertson AA, Nichols KB, Cooper MA, Stacey KJ, Ulett GC, Schroder K, Schembri MA, Sweet MJ.

Mucosal Immunol. 2016 Jan;9(1):124-36. doi: 10.1038/mi.2015.44. Epub 2015 May 20.

PMID:
25993444
22.

Molecular analysis of asymptomatic bacteriuria Escherichia coli strain VR50 reveals adaptation to the urinary tract by gene acquisition.

Beatson SA, Ben Zakour NL, Totsika M, Forde BM, Watts RE, Mabbett AN, Szubert JM, Sarkar S, Phan MD, Peters KM, Petty NK, Alikhan NF, Sullivan MJ, Gawthorne JA, Stanton-Cook M, Nhu NT, Chong TM, Yin WF, Chan KG, Hancock V, Ussery DW, Ulett GC, Schembri MA.

Infect Immun. 2015 May;83(5):1749-64. doi: 10.1128/IAI.02810-14. Epub 2015 Feb 9.

23.

Application of fragment-based screening to the design of inhibitors of Escherichia coli DsbA.

Adams LA, Sharma P, Mohanty B, Ilyichova OV, Mulcair MD, Williams ML, Gleeson EC, Totsika M, Doak BC, Caria S, Rimmer K, Horne J, Shouldice SR, Vazirani M, Headey SJ, Plumb BR, Martin JL, Heras B, Simpson JS, Scanlon MJ.

Angew Chem Int Ed Engl. 2015 Feb 9;54(7):2179-84. doi: 10.1002/anie.201410341. Epub 2014 Dec 30.

PMID:
25556635
24.

Comparative analysis of the uropathogenic Escherichia coli surface proteome by tandem mass-spectrometry of artificially induced outer membrane vesicles.

Wurpel DJ, Moriel DG, Totsika M, Easton DM, Schembri MA.

J Proteomics. 2015 Feb 6;115:93-106. doi: 10.1016/j.jprot.2014.12.005. Epub 2014 Dec 20.

PMID:
25534882
25.

Sortase A: an ideal target for anti-virulence drug development.

Cascioferro S, Totsika M, Schillaci D.

Microb Pathog. 2014 Dec;77:105-12. doi: 10.1016/j.micpath.2014.10.007. Epub 2014 Oct 18. Review.

PMID:
25457798
26.

The co-transcriptome of uropathogenic Escherichia coli-infected mouse macrophages reveals new insights into host-pathogen interactions.

Mavromatis CH, Bokil NJ, Totsika M, Kakkanat A, Schaale K, Cannistraci CV, Ryu T, Beatson SA, Ulett GC, Schembri MA, Sweet MJ, Ravasi T.

Cell Microbiol. 2015 May;17(5):730-46. doi: 10.1111/cmi.12397. Epub 2015 Jan 24.

27.

The complete genome sequence of Escherichia coli EC958: a high quality reference sequence for the globally disseminated multidrug resistant E. coli O25b:H4-ST131 clone.

Forde BM, Ben Zakour NL, Stanton-Cook M, Phan MD, Totsika M, Peters KM, Chan KG, Schembri MA, Upton M, Beatson SA.

PLoS One. 2014 Aug 15;9(8):e104400. doi: 10.1371/journal.pone.0104400. eCollection 2014.

28.

Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli.

Sarkar S, Ulett GC, Totsika M, Phan MD, Schembri MA.

PLoS One. 2014 Apr 10;9(4):e94786. doi: 10.1371/journal.pone.0094786. eCollection 2014.

29.

Global dissemination of a multidrug resistant Escherichia coli clone.

Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, Phan MD, Gomes Moriel D, Peters KM, Davies M, Rogers BA, Dougan G, Rodriguez-Baño J, Pascual A, Pitout JD, Upton M, Paterson DL, Walsh TR, Schembri MA, Beatson SA.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5694-9. doi: 10.1073/pnas.1322678111. Epub 2014 Mar 31.

30.

F9 fimbriae of uropathogenic Escherichia coli are expressed at low temperature and recognise Galβ1-3GlcNAc-containing glycans.

Wurpel DJ, Totsika M, Allsopp LP, Hartley-Tassell LE, Day CJ, Peters KM, Sarkar S, Ulett GC, Yang J, Tiralongo J, Strugnell RA, Jennings MP, Schembri MA.

PLoS One. 2014 Mar 26;9(3):e93177. doi: 10.1371/journal.pone.0093177. eCollection 2014.

31.

The antigen 43 structure reveals a molecular Velcro-like mechanism of autotransporter-mediated bacterial clumping.

Heras B, Totsika M, Peters KM, Paxman JJ, Gee CL, Jarrott RJ, Perugini MA, Whitten AE, Schembri MA.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):457-62. doi: 10.1073/pnas.1311592111. Epub 2013 Dec 13.

32.

The serum resistome of a globally disseminated multidrug resistant uropathogenic Escherichia coli clone.

Phan MD, Peters KM, Sarkar S, Lukowski SW, Allsopp LP, Gomes Moriel D, Achard ME, Totsika M, Marshall VM, Upton M, Beatson SA, Schembri MA.

PLoS Genet. 2013;9(10):e1003834. doi: 10.1371/journal.pgen.1003834. Epub 2013 Oct 3.

33.

Molecular analysis of the Acinetobacter baumannii biofilm-associated protein.

Goh HM, Beatson SA, Totsika M, Moriel DG, Phan MD, Szubert J, Runnegar N, Sidjabat HE, Paterson DL, Nimmo GR, Lipman J, Schembri MA.

Appl Environ Microbiol. 2013 Nov;79(21):6535-43. doi: 10.1128/AEM.01402-13. Epub 2013 Aug 16.

34.

A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131.

Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, Hultgren SJ, Schembri MA.

J Infect Dis. 2013 Sep;208(6):921-8. doi: 10.1093/infdis/jit245. Epub 2013 Jun 3.

35.

Molecular characterization of endocarditis-associated Staphylococcus aureus.

Nethercott C, Mabbett AN, Totsika M, Peters P, Ortiz JC, Nimmo GR, Coombs GW, Walker MJ, Schembri MA.

J Clin Microbiol. 2013 Jul;51(7):2131-8. doi: 10.1128/JCM.00651-13. Epub 2013 Apr 24.

36.

Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection.

Ulett GC, Totsika M, Schaale K, Carey AJ, Sweet MJ, Schembri MA.

Curr Opin Microbiol. 2013 Feb;16(1):100-7. doi: 10.1016/j.mib.2013.01.005. Epub 2013 Feb 8. Review.

PMID:
23403118
37.

Chaperone-usher fimbriae of Escherichia coli.

Wurpel DJ, Beatson SA, Totsika M, Petty NK, Schembri MA.

PLoS One. 2013;8(1):e52835. doi: 10.1371/journal.pone.0052835. Epub 2013 Jan 30.

38.

Functional heterogeneity of the UpaH autotransporter protein from uropathogenic Escherichia coli.

Allsopp LP, Beloin C, Moriel DG, Totsika M, Ghigo JM, Schembri MA.

J Bacteriol. 2012 Nov;194(21):5769-82. doi: 10.1128/JB.01264-12. Epub 2012 Aug 17.

39.

Escherichia coli 83972 expressing a P fimbriae oligosaccharide receptor mimic impairs adhesion of uropathogenic E. coli.

Watts RE, Tan CK, Ulett GC, Carey AJ, Totsika M, Idris A, Paton AW, Morona R, Paton JC, Schembri MA.

J Infect Dis. 2012 Oct;206(8):1242-9. Epub 2012 Aug 7.

PMID:
22872729
40.

Identification of genes important for growth of asymptomatic bacteriuria Escherichia coli in urine.

Vejborg RM, de Evgrafov MR, Phan MD, Totsika M, Schembri MA, Hancock V.

Infect Immun. 2012 Sep;80(9):3179-88. doi: 10.1128/IAI.00473-12. Epub 2012 Jul 2.

41.

Uropathogenic Escherichia coli mediated urinary tract infection.

Totsika M, Moriel DG, Idris A, Rogers BA, Wurpel DJ, Phan MD, Paterson DL, Schembri MA.

Curr Drug Targets. 2012 Oct;13(11):1386-99.

PMID:
22664092
42.

Discovery of an archetypal protein transport system in bacterial outer membranes.

Selkrig J, Mosbahi K, Webb CT, Belousoff MJ, Perry AJ, Wells TJ, Morris F, Leyton DL, Totsika M, Phan MD, Celik N, Kelly M, Oates C, Hartland EL, Robins-Browne RM, Ramarathinam SH, Purcell AW, Schembri MA, Strugnell RA, Henderson IR, Walker D, Lithgow T.

Nat Struct Mol Biol. 2012 Apr 1;19(5):506-10, S1. doi: 10.1038/nsmb.2261.

PMID:
22466966
43.

Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ.

FEMS Microbiol Rev. 2012 May;36(3):616-48. doi: 10.1111/j.1574-6976.2012.00339.x. Review.

44.

Molecular characterization of the EhaG and UpaG trimeric autotransporter proteins from pathogenic Escherichia coli.

Totsika M, Wells TJ, Beloin C, Valle J, Allsopp LP, King NP, Ghigo JM, Schembri MA.

Appl Environ Microbiol. 2012 Apr;78(7):2179-89. doi: 10.1128/AEM.06680-11. Epub 2012 Jan 27.

45.

Characterisation of a cell wall-anchored protein of Staphylococcus saprophyticus associated with linoleic acid resistance.

King NP, Sakinç T, Ben Zakour NL, Totsika M, Heras B, Simerska P, Shepherd M, Gatermann SG, Beatson SA, Schembri MA.

BMC Microbiol. 2012 Jan 15;12:8. doi: 10.1186/1471-2180-12-8.

46.

Molecular characterization of Escherichia coli strains that cause symptomatic and asymptomatic urinary tract infections.

Abraham S, Chapman TA, Zhang R, Chin J, Mabbett AN, Totsika M, Schembri MA.

J Clin Microbiol. 2012 Mar;50(3):1027-30. doi: 10.1128/JCM.06671-11. Epub 2011 Dec 21.

47.

Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection.

Duell BL, Carey AJ, Tan CK, Cui X, Webb RI, Totsika M, Schembri MA, Derrington P, Irving-Rodgers H, Brooks AJ, Cripps AW, Crowley M, Ulett GC.

J Immunol. 2012 Jan 15;188(2):781-92. doi: 10.4049/jimmunol.1101231. Epub 2011 Dec 19.

48.

Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms.

Totsika M, Beatson SA, Sarkar S, Phan MD, Petty NK, Bachmann N, Szubert M, Sidjabat HE, Paterson DL, Upton M, Schembri MA.

PLoS One. 2011;6(10):e26578. doi: 10.1371/journal.pone.0026578. Epub 2011 Oct 28.

49.

Molecular characterization of UpaB and UpaC, two new autotransporter proteins of uropathogenic Escherichia coli CFT073.

Allsopp LP, Beloin C, Ulett GC, Valle J, Totsika M, Sherlock O, Ghigo JM, Schembri MA.

Infect Immun. 2012 Jan;80(1):321-32. doi: 10.1128/IAI.05322-11. Epub 2011 Sep 19.

50.

Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli.

Watts RE, Totsika M, Challinor VL, Mabbett AN, Ulett GC, De Voss JJ, Schembri MA.

Infect Immun. 2012 Jan;80(1):333-44. doi: 10.1128/IAI.05594-11. Epub 2011 Sep 19.

Supplemental Content

Loading ...
Support Center